Great Lakes Advisors LLC Reduces Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Great Lakes Advisors LLC cut its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSMFree Report) by 19.2% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 13,508 shares of the company’s stock after selling 3,220 shares during the quarter. Great Lakes Advisors LLC’s holdings in Axsome Therapeutics were worth $1,143,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of AXSM. Assetmark Inc. purchased a new stake in Axsome Therapeutics during the 4th quarter worth approximately $52,000. R Squared Ltd purchased a new stake in Axsome Therapeutics during the 4th quarter worth approximately $64,000. KBC Group NV increased its holdings in Axsome Therapeutics by 40.5% during the 4th quarter. KBC Group NV now owns 1,336 shares of the company’s stock worth $113,000 after purchasing an additional 385 shares during the last quarter. Moors & Cabot Inc. purchased a new stake in Axsome Therapeutics during the 3rd quarter worth approximately $200,000. Finally, Whalen Wealth Management Inc. purchased a new stake in Axsome Therapeutics during the 3rd quarter worth approximately $236,000. 81.49% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CFO Nick Pizzie sold 3,000 shares of the company’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $131.07, for a total transaction of $393,210.00. Following the completion of the sale, the chief financial officer now directly owns 42,187 shares of the company’s stock, valued at $5,529,450.09. This represents a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 22.40% of the company’s stock.

Analyst Upgrades and Downgrades

AXSM has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft initiated coverage on Axsome Therapeutics in a report on Tuesday, February 11th. They issued a “buy” rating and a $176.00 price target for the company. Mizuho boosted their price target on Axsome Therapeutics from $195.00 to $212.00 and gave the company an “outperform” rating in a report on Wednesday, February 26th. William Blair reiterated an “outperform” rating on shares of Axsome Therapeutics in a report on Tuesday, February 18th. Robert W. Baird boosted their price target on Axsome Therapeutics from $132.00 to $160.00 and gave the company an “outperform” rating in a report on Monday, March 3rd. Finally, Leerink Partners boosted their price target on Axsome Therapeutics from $110.00 to $150.00 and gave the company an “outperform” rating in a report on Monday, February 10th. One research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $167.36.

Read Our Latest Stock Report on AXSM

Axsome Therapeutics Trading Up 0.2 %

Shares of Axsome Therapeutics stock opened at $121.91 on Friday. The company has a quick ratio of 2.04, a current ratio of 2.11 and a debt-to-equity ratio of 3.22. The firm has a market cap of $5.94 billion, a price-to-earnings ratio of -20.35 and a beta of 1.00. The business has a fifty day simple moving average of $112.25 and a 200-day simple moving average of $98.88. Axsome Therapeutics, Inc. has a fifty-two week low of $64.11 and a fifty-two week high of $139.13.

Axsome Therapeutics (NASDAQ:AXSMGet Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, beating the consensus estimate of ($0.97) by $0.01. The business had revenue of $118.77 million during the quarter, compared to analyst estimates of $117.83 million. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. On average, equities analysts forecast that Axsome Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Axsome Therapeutics Profile

(Free Report)

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.

Recommended Stories

Want to see what other hedge funds are holding AXSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSMFree Report).

Institutional Ownership by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.